Publications by authors named "John Newcomb"

Claim this Profile
P
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.
Wassilis S C Bruins, Rosa Rentenaar, John Newcomb, Wenrou Zheng, Ruud W J Ruiter

Hemasphere· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
Marc L Hyer, Michael A Milhollen, Jeff Ciavarri, Paul Fleming, Tary Traore, John Newcomb

Nat Med· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.
Xingyue He, Jessica Riceberg, Teresa Soucy, Erik Koenig, James Minissale, John Newcomb

Nat Chem Biol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.
Xingyue He, Jessica Riceberg, Sai M Pulukuri, Steve Grossman, Vaishali Shinde, John Newcomb

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Zihao Hua, Howard Bregman, John L Buchanan, Nagasree Chakka, Angel Guzman-Perez, John Newcomb

J Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Howard Bregman, Nagasree Chakka, Angel Guzman-Perez, Hakan Gunaydin, Yan Gu, John Newcomb

J Med Chem· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of Potent and Selective CK1γ Inhibitors.
Hongbing Huang, Lisa Acquaviva, Virginia Berry, Howard Bregman, Nagasree Chakka, John Newcomb

ACS Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
Zihao Hua, Xin Huang, Howard Bregman, Nagasree Chakka, Erin F DiMauro, John Newcomb

Bioorg Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
John L Buchanan, John R Newcomb, David P Carney, Stuart C Chaffee, Lilly Chai

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, Christina Boucher, Lilly Chai

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
Erin F DiMauro, John Newcomb, Joseph J Nunes, Jean E Bemis, Christina Boucher

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Holly L Deak, John R Newcomb, Joseph J Nunes, Christina Boucher, Alan C Cheng

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
Matthew W Martin, John Newcomb, Joseph J Nunes, Jean E Bemis, David C McGowan

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
Erin F DiMauro, John Newcomb, Joseph J Nunes, Jean E Bemis, Christina Boucher

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
Erin F DiMauro, John Newcomb, Joseph J Nunes, Jean E Bemis, Christina Boucher

J Med Chem· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, David C McGowan, David M Armistead

J Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis